Cure My Disease

Don't miss your cure!

 Log in / Sign up

New ointment could treat larger patches of Sun-Damaged skin

NCT ID NCT06135415

Completed Disease control Sponsor: Almirall, S.A. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times

Summary

This study tested an ointment called tirbanibulin (Klisyri®) on adults with actinic keratosis, a common precancerous skin condition caused by sun exposure. The trial included 280 participants and applied the ointment to larger skin areas (up to 100 cm²) on the face or balding scalp. The goal was to see if it safely reduces the number of lesions compared to a placebo ointment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
tirbanibulin ointment (Klisyri®)
What this could lead to
If successful, this could provide a treatment option for larger areas of actinic keratosis, reducing the number of precancerous skin lesions.
What could go wrong
This is a completed Phase 3 trial, but results are not yet published. The treatment may cause skin reactions and may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KERATOSIS, ACTINIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

actinic keratosis keratosis neoplasm precancerous condition

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KERATOSIS, ACTINIC

Contacts and locations

Locations

  • Site 1

    Bad Bentheim, Germany

  • Site 10

    Warsaw, Poland

  • Site 11

    Warsaw, Poland

  • Site 12

    Barcelona, Spain

  • Site 13

    Madrid, Spain

  • Site 14

    Barcelona, Spain

  • Site 15

    Valencia, Spain

  • Site 16

    Zaragoza, Spain

  • Site 17

    Augsburg, Germany

  • Site 18

    Dresden, Germany

  • Site 19

    Brescia, Italy

  • Site 2

    Hamburg, Germany

  • Site 20

    Roma, Italy

  • Site 21

    Roma, Italy

  • Site 22

    Pisa, Italy

  • Site 23

    Florence, Italy

  • Site 24

    Bari, Italy

  • Site 25

    Bologna, Italy

  • Site 26

    Cagliari, Italy

  • Site 27

    Reggio Emilia, Italy

  • Site 28

    Maastricht, Netherlands

  • Site 29

    Heemstede, Netherlands

  • Site 3

    Bochum, Germany

  • Site 30

    Ossy, Poland

  • Site 31

    Krakow, Poland

  • Site 32

    Salamanca, Spain

  • Site 33

    Granada, Spain

  • Site 34

    Barcelona, Spain

  • Site 35

    Valencia, Spain

  • Site 4

    Mahlow, Germany

  • Site 5

    Hamburg, Germany

  • Site 6

    Wuppertal, Germany

  • Site 7

    Roma, Italy

  • Site 8

    Wroclaw, Poland

  • Site 9

    Warsaw, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.